홈 › 급성 골수성 백혈병 › 아이오와
아이오와의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 16개가 아이오와 내 여러 지역에서 참여자를 모집하고 있습니다.
아이오와의 도시
공식 연구 텍스트(영어)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Iowa, Iowa City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07007312Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT05554406Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- 외 12개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05334069MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive
- Iowa Methodist Medical Center, Des Moines
- 외 7개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT05564390Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Iowa Hospitals and Clinics, Iowa City
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT05429632Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT05554393A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Iowa Hospital, Iowa City
피험자 모집 중1/2상
30 Days · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT04065399A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Iowa Hospital and Clinics, Iowa City
피험자 모집 중관찰 연구
0세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT07154823A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
피험자 모집 중3상
6 Months – 21 Years · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT04293562Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Blank Children's Hospital, Des Moines
피험자 모집 중3상
1세 ~ 25세 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07022678High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
- University of Iowa Health Care, Iowa City
피험자 모집 중1상
18세 ~ 75세 · 모든 성별 · 2026. 8. 31. 업데이트됨 · NCT07177079The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Iowa Hospitals & Clinics, Iowa City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 20. 업데이트됨 · NCT06001788A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Iowa, Iowa City
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Iowa Hospitals & Clinics, Iowa City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 13. 업데이트됨 · NCT05735184ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.